跳至主要内容
临床试验/ACTRN12615000121561
ACTRN12615000121561终止3 期

A randomised, double-blind, multi-site, parallel arm, fixed dose, placebo-controlled trial of the effects of morphine on exercise capacity and other outcomes of pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD)

Flinders University0 个研究点目标入组 260 人开始时间: 2015年2月10日最近更新:
适应症

试验速览

阶段
3 期
状态
终止
入组人数
260

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • * Eligible for pulmonary rehabilitation as judged by the treating physician and the investigator
  • * COPD verified by a post-bronchodilator FEV1/FVC<0.7 on a previous spirometry
  • * Age 18 years or more
  • * English speaking and able to read study questionnaires (5th grade level)
  • * On stable medications for breathlessness over the prior week except routine as needed” medications
  • * Participant is capable of giving informed written consent, completing assessments, and complying with the study procedures
  • * Breathlessness of a level 3 or 4 on the mMRC dyspnoea scale

排除标准

  • * Unstable cardiac or vascular disease within the previous four weeks.
  • * Severely restricted performance status with AKPS score < 50 at baseline.
  • * Anaemia with hemoglobin <10.0g/dL as measured within one month of baseline evaluation for which transfusion would be indicated in the view of the treating physician.
  • * History of chronic alcoholism or drug misuse problem.
  • * On regular or ‘as needed’ (PRN) opioid medications, including codeine preparations at or above a dose equivalent to 20mg of morphine sulphate per 24 hours.
  • * Renal dysfunction with creatinine clearance calculated <20 mls/minute using the MDRD formula. (Severe renal impairment – AMH)
  • * Hepatic impairment with serum alkaline phosphatase, total bilirubin, ALT or AST > four times the upper limit of normal for the local laboratory.
  • * Documented central hypoventilation syndrome.
  • * Evidence of respiratory depression with resting respiratory rate < 8.
  • * Participation in the current study at any time, or in a clinical study of a new chemical entity within the month prior to study entry
  • * History of adverse reactions to morphine or constituents in the placebo.
  • * Pregnant or breastfeeding.
  • * Unable to achieve two baseline 6MWTs of at least 200m each

研究者

相似试验